Previous 10 | Next 10 |
Gainers: CNFR +22.2% . VNDA +19.9% . IFRX +18.1% . DXCM +17.5% . IVC +15.6% . More news on: Conifer Holdings, Inc., Vanda Pharmaceuticals Inc., InflaRx N.V., Stocks on the move, Read more ...
The Sell-Off ChemoCentryx ( CCXI ) is a clinical-stage small market cap ($390M) biopharma developing innovative chemokine-based therapeutics for rare, autoimmune and oncological diseases. Since my last article in late May/2019, CCXI share price has depreciated 50%. The stock price deprecia...
IFX-1 in Hidradenitis Suppurativa did not meet the primary endpoint; trial ongoing - multiple efficacy signals for high-dose group identified First patient treated in Pyoderma Gangraenosum phase IIa trial Second phase II clinical trial commenced in ANCA-associated vasculitis Cash and ca...
InflaRx (NASDAQ: IFRX ) is up 6% after hours on the heels of additional data from its Phase 2b clinical trial, SHINE , evaluating IFX-1 in patients with moderate-to-severe hidradenitis suppurativa, a painful inflammatory skin disorder. More news on: InflaRx N.V., Healthcare ...
IFX-1 treatment in high dose group resulted in multiple efficacy signals supporting further development of IFX-1 in HS IFX-1 suppressed C5a levels dose dependently and exhibited a favorable safety profile with low anti-drug antibody rates Open-label extension study is ongoing, InflaRx pl...
InflaRx (NASDAQ: IFRX ) is up 7% premarket on modest volume in reaction to its announcement that the first patient has been dosed in a Phase 2a clinical trial evaluating lead candidate IFX-1 in patients with pyoderma gangrenosum , a rare skin condition characterized by large...
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers JENA, Germany, June 13, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the compl...
Provention Bio (NASDAQ: PRVB ) +170% on potential of teplizumab to delay diabetes. More news on: Provention Bio, Inc., Tableau Software, Inc., Tilray, Inc., Stocks on the move, Read more ...
Editor's note: Seeking Alpha is proud to welcome Cory Jubinville as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Results for Inf...
ContraVir Pharmaceuticals (NASDAQ: CTRV ) +123% on encouraging CRV431 data . More news on: ContraVir Pharmaceuticals, Inc., Stitch Fix, Inc., Ciena Corporation, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...